This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar

5.1.4 Treatment Usage Patterns 36

5.1.5 Treatment Flow Algorithm 38

5.1.6 Drivers and Barriers for the Osteoporosis Therapeutics Market 39

5.2 Paget's Disease of Bone Therapeutics Market 40

5.2.1 Introduction 40

5.2.2 Revenue 40

5.2.3 Annual Cost of Treatment 45

5.2.4 Treatment Usage Patterns 46

5.2.5 Treatment Flow Algorithm 48

5.2.6 Drivers and Barriers for the Paget's Disease of Bone Therapeutics Market 49

5.3 Hyperparathyroidism Therapeutics Market 50

5.3.1 Introduction 50

5.3.2 Revenue 50

5.3.3 Annual Cost of Treatment 55

5.3.4 Treatment Usage Patterns 56

5.3.5 Treatment Flow Algorithm 58

5.3.6 Drivers and Barriers for the Hyperparathyroidism Therapeutics Market 59

5.4 Bone Metastases Therapeutics Market 60

5.4.1 Introduction 60

5.4.2 Revenue 60

5.4.3 Annual Cost of Treatment 65

5.4.4 Treatment Usage Patterns 66

5.4.5 Treatment Flow Algorithm 68

5.4.6 Drivers and Barriers for the Bone Metastases Therapeutics Market 68

6 Bone Metabolism Therapeutics Market to 2018 - Pipeline Analysis 70

6.1 Introduction 70

6.2 Bone Metabolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 72

6.2.1 Filed Molecules 72

6.2.2 Phase III 73

6.2.3 Phase II 78

6.2.4 Phase I 80

6.2.5 Preclinical Phase 81

6.2.6 Discovery Phase 82

6.3 Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market 82

6.3.1 Alpharadin (radium-223 chloride) 82

6.3.2 Orazol (Zoledronic acid) 83

6.3.3 Xgeva (denosumab) 83

6.3.4 Boniva (ibandronate sodium hydrate) 84

6.3.5 Odanacatib (odanacatib) 85

6.3.6 GTH-42V 85

6.3.7 Viviant (bazedoxifene) 86

7 Bone Metabolism Therapeutics Market to 2018 - Competitive Profiling 87

7.1 Competitive Profiling 87

7.1.1 Amgen Inc. 87

7.1.2 Abbott Laboratories 89

7.1.3 Genzyme Corporation 90

7.1.4 Merck & Co., Inc. 91

7.1.5 Novartis AG 93

8 Bone Metabolism Therapeutics Market to 2018 - Strategic Consolidations 95

8.1 Mergers and Acquisitions 95

8.1.1 Segmentation by Deal Value 97

8.1.2 Segmentation by Geography 99

8.2 Co-development Deals 100

4 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,660.03 -12.57 -0.07%
S&P 500 2,055.21 +3.39 0.17%
NASDAQ 4,768.5660 +10.6870 0.22%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs